Version June 2024
| Historical |
| Poor symptom control over the past 4 weeks |
| ≥1 exacerbations in the previous year |
| Prior intensive care unit admission and/or endotracheal intubation for asthma |
| Comorbid diseases |
| Obesity |
| Chronic obstructive pulmonary disease |
| Chronic rhinosinusitis (particularly with nasal polyposis) |
| Uncontrolled allergic rhinitis |
| Gastroesophageal reflux disease |
| Aspirin-exacerbated respiratory disease |
| IgE-mediated food allergies |
| Pregnancy |
| Anxiety |
| Depression |
| Medication-associated |
| Poor adherence to prescribed anti-inflammatory therapies (eg, inhaled glucocorticoids, ICS-LABA, anti-leukotrienes) |
| Incorrect inhaler technique or difficulty with administration |
| High SABA use (especially >200-doses per month or three 200-dose canisters per year) |
| Exposures/triggers |
| Smoking |
| Second-hand smoke exposure |
| Allergen exposure (if sensitized) |
| Respiratory viral infections |
| Air pollution |
| Excess heat or cold exposures |
| Recurrent exposure to airborne irritants |
| Cocaine or heroin use (especially when inhaled) |
| Diagnostic testing |
| Impaired lung function (especially FEV1 <60% predicted) |
| High reversibility (FEV1 improvement by >15%) on post-bronchodilator spirometry |
| Elevated type 2 inflammatory markers* despite medium- to high-dose ICS-LABA |
| Access to care |
| Difficulty affording asthma therapies |
| Lack of insurance or other difficulty obtaining regular follow-up |
FEV1: forced expiratory volume in one second; ICS-LABA: inhaled corticosteroids-long-acting beta-agonist; IgE: immunoglobulin E; SABA: short-acting beta-agonist.
* Sputum/blood eosinophilia, fraction of exhaled nitric oxide (FeNO).آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
